Reference - Detail
| RRC ID | 3014 |
|---|---|
| Author | Park BJ, Park JC, Taguchi H, Fukushima K, Hyon SH, Takatori K. |
| Title | Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. |
| Journal | Biochem Biophys Res Commun |
| Abstract |
This is the first report to investigate the antifungal susceptibility of 21 clinical isolates of seven Candida species to epigallocatechin 3-O-gallate (EGCg) and to compare with six antifungal agents, amphotericin B (AMPH), fluconazole (FLCZ), flucytosin (5FC), itraconazole (ITCZ), micafungin (MCFG), and miconazole (MCZ), using a method following the National Committee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Among the tested species, Candida glabrata exhibited the highest susceptibility to EGCg (MIC50, 0.5-1 microg/ml and MIC90, 1-2 microg/ml) compared favorably with FLCZ, although they were slightly less susceptible than to AMPH, 5FC, MCFG, ITCZ, and MCZ. Candida guilliemondii and Candida parapsilosis (MIC50, 1-4 microg/ml and MIC90, 2-16 microg/ml) were also susceptible to EGCg, although they appear to be slightly less susceptible to EGCg than C. glabrata and the other antifungal agents tested. Moreover, the susceptibility of Candida krusei strains (MIC50, 2 microg/ml and MIC90, 4-8 microg/ml) to EGCg was approximately 2- to 8-fold higher than those of 5FC and FLCZ. Our data indicate that EGCg can inhibit clinically pathogenic Candida species, although the concentrations of EGCg for antifungal susceptibility were slightly higher than those of tested antifungal agents on the whole. Based on these results, we suggest that EGCg may be effectively used as a possible agent or adjuvant for antifungal therapy in Candidiasis. |
| Volume | 347(2) |
| Pages | 401-5 |
| Published | 2006-8-25 |
| DOI | 10.1016/j.bbrc.2006.06.037 |
| PII | S0006-291X(06)01344-1 |
| PMID | 16831406 |
| MeSH | Amphotericin B / pharmacology Antifungal Agents / pharmacology* Candida / drug effects* Candida / growth & development Candida / isolation & purification Candidiasis / microbiology Catechin / analogs & derivatives* Catechin / pharmacology Dose-Response Relationship, Drug Echinocandins Fluconazole / pharmacology Flucytosine / pharmacology Humans Itraconazole / pharmacology Lipopeptides Lipoproteins / pharmacology Micafungin Miconazole / pharmacology Microbial Sensitivity Tests / methods Peptides, Cyclic / pharmacology Species Specificity |
| IF | 2.985 |
| Times Cited | 45 |
| WOS Category | BIOPHYSICS BIOCHEMISTRY & MOLECULAR BIOLOGY |
| Resource | |
| Pathogenic microorganisms | C. parapsilosis(IFM 5747) C. krusei(IFM 5749) C. glabrata(IFM 5768) C.guilliemondii (IFM 5775) C. tropicalis(IFM 5797) C. krusei(IFM 5798) C. glabrata(IFM 5799) C. albicans(IFM 5801) C. parapsilosis(IFM 5804) C. albicans(IFM 40213) C. albicans(IFM 40214) C. glabrata(IFM 40217) C. parapsilosis(IFM 40218) C. tropicalis(IFM 46066) C. tropicalis(IFM 46820) C.guilliemondii (IFM 46824) C.guilliemondii (IFM 46826) C. krusei(IFM 46838) C. dubliniensis(IFM 48184) C. dubliniensis(IFM 48313) C. dubliniensis(IFM 48314) |